Evidence map›Paper›PMID 32859246›Full record

ArticleJournal of experimental & clinical cancer research : CR2020

Lysine-222 succinylation reduces lysosomal degradation of lactate dehydrogenase a and is increased in gastric cancer.

Xiang Li, Chen Zhang, Ting Zhao, Zhongping Su, Mengjing Li, Jiancheng Hu, Jianfei Wen, Jiajia Shen, Chao Wang, Jinshun Pan and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 127 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. The moonlighting functions of glycolytic enzymes in tumorigenesis.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Xiang LiAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Chen ZhangDepartment of Biotherapy, Department of Surgery, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Ting ZhaoAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Zhongping SuDepartment of Biotherapy, Department of Surgery, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Mengjing LiDepartment of Biotherapy, Department of Surgery, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Jiancheng HuDivision of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Jianfei WenThe First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Jiajia ShenThe First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Chao WangDepartment of Biotherapy, Department of Surgery, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Jinshun PanDepartment of Biotherapy, Department of Surgery, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Xianmin MuDepartment of Biotherapy, Department of Surgery, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Tao LingDepartment of Biotherapy, Department of Surgery, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Yingchang LiAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Hao WenDepartment of Biotherapy, Department of Surgery, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Xiaoren ZhangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Qiang YouAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. qiang.you@live.com.ORCID http://orcid.org/0000-0003-3308-4127
Second Affiliated Hospital of Nanjing Medical University · CNGuangzhou Medical University · CNJiangsu Province Hospital · CNDuke-NUS Medical School · SGNanjing University of Chinese Medicine · CN

Funding

National Natural Science Foundation of China 81671543National Natural Science Foundation of China 81802464National Natural Science Foundation of China 81870409
6 · The paper itself

Abstract

backgroundLysine succinylation is an emerging posttranslational modification that has garnered increased attention recently, but its role in gastric cancer (GC) remains underexplored.

methodsProteomic quantification of lysine succinylation was performed in human GC tissues and adjacent normal tissues by mass spectrometry. The mRNA and protein levels of lactate dehydrogenase A (LDHA) in GC and adjacent normal tissues were analyzed by qRT-PCR and western blot, respectively. The expression of K222-succinylated LDHA was measured in GC tissue microarray by the K222 succinylation-specific antibody. The interaction between LDHA and sequestosome 1 (SQSTM1) was measured by co-immunoprecipitation (co-IP) and proximity ligation assay (PLA). The binding of carnitine palmitoyltransferase 1A (CPT1A) to LDHA was determined by co-IP. The effect of K222-succinylated LDHA on tumor growth and metastasis was evaluated by in vitro and in vivo experiments.

resultsAltogether, 503 lysine succinylation sites in 303 proteins were identified. Lactate dehydrogenase A (LDHA), the key enzyme in Warburg effect, was found highly succinylated at K222 in GC. Intriguingly, this modification did not affect LDHA ubiquitination, but reduced the binding of ubiquitinated LDHA to SQSTM1, thereby decreasing its lysosomal degradation. We demonstrated that CPT1A functions as a lysine succinyltransferase that interacts with and succinylates LDHA. Moreover, high K222-succinylation of LDHA was associated with poor prognosis in patients with GC. Finally, overexpression of a succinylation-mimic mutant of LDHA promoted cell proliferation, invasion, and migration.

conclusionsOur data revealed a novel lysosomal pathway of LDHA degradation, which is mediated by the binding of K63-ubiquitinated LDHA to SQSTM1. Strikingly, CPT1A succinylates LDHA on K222, which thereby reduces the binding and inhibits the degradation of LDHA, as well as promotes GC invasion and proliferation. This study thus uncovers a new role of lysine succinylation and the mechanism underlying LDHA upregulation in GC.

Indexed as

Protein Processing, Post-TranslationalAnimalsApoptosisBiomarkers, TumorCarnitine O-PalmitoyltransferaseCell ProliferationFemaleGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansL-Lactate DehydrogenaseLung NeoplasmsLysineLysosomesMaleMelanomaBiomarkers, TumorCarnitine O-PalmitoyltransferaseCPT1A protein, humanLDHA protein, humanL-Lactate DehydrogenaseLysineSequestosome-1 ProteinSQSTM1 protein, humanSuccinic AcidCPT1AGastric cancerLDHALysine succinylationSQSTM1

Identifiers

PMID32859246
PMCPMC7455916
OpenAlexW3082456962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.